Ajanta Pharma has informed that Board of Directors of the Company, at its meeting held today December 28, 2021, has unanimously approved Buy-back of up to 11,20,000 fully paid-up Equity Shares of face value of Rs 2 each by the Company (representing 1.29% of the total number of Equity Shares of the Company) at a price of Rs 2,550 (Rupees Two Thousand Five Hundred and Fifty only) per Equity Share payable in cash for a total consideration not exceeding Rs 285.60 crores (Rupees Two Hundred Eighty Five Crores and Sixty Lakhs only) (excluding transaction costs such as fees, brokerage, taxes, duties, etc.), which is not exceeding 10% of the total paid-up equity share capital and free reserves (including securities premium account) as per the audited financial statements of the Company for the financial year ended on March 31, 2021, through the 'Tender Offer' route.
The above information is a part of company’s filings submitted to BSE.
